Blog - Factor-H

Factor-H team visiting a person affected by Huntington’s disease

Hope in Numbers: More than 2,000 people from the Huntington’s community in Venezuela benefited from Factor-H programs during the third quarter of 2025

October 16, 2025 No Comments

During the third quarter of 2025, Factor-H, in partnership with Hábitat Luz, expanded its impact in the communities of San Luis and Barranquitas, reaching a total of 2,045 people, including individuals with Huntington’s disease (HD), their families, and children from the Abrazos Program.

"La veda" is the period of time when fishing is forbidden.

To the Rhythm of the veda – Al ritmo de la veda

October 13, 2025 No Comments

At first, going to Barranquitas felt like stepping into the world of Mad Max. The heat, the dust, the precariousness, the sense that everything could

Factor-H at Cuidarme, Cuidarte in Medellín

October 2, 2025 No Comments

The city of Medellín hosted Cuidarme, Cuidarte, a gathering that brought together social organizations, health institutions, community groups, and families to share experiences and knowledge

Interview with Ignacio Muñoz-Sanjuán – Reflections on UniQure’s AMT-130 study

September 29, 2025 2 Comments

Explanation in Spanish of the meaning of UniQure’s new AMT-130 therapy, with clarifications on the what and the when, by Dr. Ignacio Muñoz-Sanjuán (based on the most recent study published on September 24, 2025)

AMT-130 Marks a Historic Moment for Huntington’s—Now Comes Careful Communication

September 28, 2025 8 Comments

On July 10, 2024, I wrote a reflection piece following the investor conference where uniQure presented the encouraging 24-month results of AMT-130, the first HTT-directed

Image of the BBC page announcing treatment for Huntington’s disease

Ignacio Muñoz-Sanjuan: “We may see a Huntington’s therapy approved in 2026. It is a day for hope: while the therapy will at first be limited, access will increase in the years ahead”

September 24, 2025 No Comments

24/09/2025 Ignacio Muñoz-Sanjuan, neuroscientist and founder of the non-profit Factor-H, has expressed optimism that an experimental gene therapy for Huntington’s disease, developed by uniQure and

Hope in Numbers: More than 2,000 people from the Huntington’s community in Venezuela benefited from Factor-H programs during the third quarter of 2025

To the Rhythm of the veda – Al ritmo de la veda

Factor-H at Cuidarme, Cuidarte in Medellín

Interview with Ignacio Muñoz-Sanjuán – Reflections on UniQure’s AMT-130 study

AMT-130 Marks a Historic Moment for Huntington’s—Now Comes Careful Communication

Ignacio Muñoz-Sanjuan: “We may see a Huntington’s therapy approved in 2026. It is a day for hope: while the therapy will at first be limited, access will increase in the years ahead”

follow us

OTHERS HD LINKS

MEET BRAYAN

Contact us at:

Subscribe:

Follow our Channels:

Hope in Numbers: More than 2,000 people from the Huntington’s community in Venezuela benefited from Factor-H programs during the third quarter of 2025

To the Rhythm of the veda – Al ritmo de la veda

Factor-H at Cuidarme, Cuidarte in Medellín

Interview with Ignacio Muñoz-Sanjuán – Reflections on UniQure’s AMT-130 study

AMT-130 Marks a Historic Moment for Huntington’s—Now Comes Careful Communication

Ignacio Muñoz-Sanjuan: “We may see a Huntington’s therapy approved in 2026. It is a day for hope: while the therapy will at first be limited, access will increase in the years ahead”

follow us

Categories

OTHERS HD LINKS

MEET BRAYAN